Advanced search
Publication Cover
mAbs Volume 3, 2011 - Issue 2
Submit an article Journal homepage
7,131
Views
148
CrossRef citations to date
0
Altmetric
Point of View

Worldwide experience with biosimilar development

Mark McCamish Head Global Biopharmaceutical Development; Sandoz Biopharmaceuticals
&
Gillian Woollett Chief Scientist; Engel & Novitt, LLP Correspondence[email protected]
Pages 209-217 | Received 27 Jan 2011, Accepted 30 Jan 2011, Published online: 01 Mar 2011

Citations (148)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (22)

GM Murray, N Griffith, P Sinnappurajar, DA Al Julandani, SLN Clarke, DP Hawley, J Choi, CM Guly & Athimalaipet V Ramanan. (2023) Clinical Efficacy of Biosimilar Switch of Adalimumab for Management of Uveitis. Ocular Immunology and Inflammation 0:0, pages 1-5.
Read now
Ekaterina Raykova, Mohammad Farmahini Farahani, Stanislava Ivanova & Morteza Azhdarzadeh. (2022) A randomized pharmacokinetic/pharmacodynamic study comparing the bioequivalence of potential biosimilar candidate P044 with reference medicine in healthy volunteers. Expert Opinion on Biological Therapy 22:2, pages 235-243.
Read now
Artem Zharkov, Bettina Barton, Dominik Heinzmann, Georgios Bakalos & Thomas Schreitmüller. (2022) Development pathways for subcutaneous formulations of biologics versus biosimilar development. Expert Review of Precision Medicine and Drug Development 7:1, pages 62-69.
Read now
Joon-Cheol Kwon, O Hwan Kwon, Rae Ung Jeong, Nayoun Kim, Seonah Song, Ilsub Choi, Juneok Lee & Takahiko Horiuchi. (2021) Physicochemical and biological similarity assessment of LBAL, a biosimilar to adalimumab reference product (Humira®). Animal Cells and Systems 25:3, pages 182-194.
Read now
Krisztina B. Gecse, Fraser Cumming & Geert D’Haens. (2019) Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients’ concerns?. Expert Review of Gastroenterology & Hepatology 13:2, pages 143-155.
Read now
Ulrich Kronthaler, Cornelius Fritsch, Otmar Hainzl, Andreas Seidl & Antonio da Silva. (2018) Comparative functional and pharmacological characterization of Sandoz proposed biosimilar adalimumab (GP2017): rationale for extrapolation across indications. Expert Opinion on Biological Therapy 18:8, pages 921-930.
Read now
Simrun Grewal, Scott Ramsey, Sanjeev Balu & Josh J. Carlson. (2018) Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim. Expert Review of Pharmacoeconomics & Outcomes Research 18:4, pages 447-454.
Read now
Virginia Acha & Jorge Mestre-Ferrandiz. (2017) Translating European regulatory approval into healthcare uptake for biosimilars: the second translational gap. Technology Analysis & Strategic Management 29:3, pages 263-275.
Read now
Laurent Magnenat, Angelo Palmese, Christèle Fremaux, Fabio D'Amici, Mariagrazia Terlizzese, Mara Rossi & Laurent Chevalet. (2017) Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®. mAbs 9:1, pages 127-139.
Read now
Tommaso Gabbani, Simona Deiana, Siro Bagnoli & Vito Annese. (2016) Development, safety, and efficacy of biosimilar adalimumab: the data so far. Biosimilars 6, pages 1-7.
Read now
Molly Campa, Caitriona Ryan & Alan Menter. (2015) An overview of developing TNF-α targeted therapy for the treatment of psoriasis. Expert Opinion on Investigational Drugs 24:10, pages 1343-1354.
Read now
Ewald TJ van den Bremer, Frank J Beurskens, Marleen Voorhorst, Patrick J Engelberts, Rob N de Jong, Burt G van der Boom, Erika M Cook, Margaret A Lindorfer, Ronald P Taylor, Patrick HC van Berkel & Paul WHI Parren. (2015) Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation. mAbs 7:4, pages 672-680.
Read now
Parminder Kaur, Sara E Tomechko, Janna Kiselar, Wuxian Shi, Galahad Deperalta, Aaron T Wecksler, Giridharan Gokulrangan, Victor Ling & Mark R Chance. (2015) Characterizing monoclonal antibody structure by carboxyl group footprinting. mAbs 7:3, pages 540-552.
Read now
Martin K Kuhlmann & Andrea Schmidt. (2014) Production and manufacturing of biosimilar insulins: implications for patients, physicians, and health care systems. Biosimilars 4, pages 45-58.
Read now
Parminder Kaur, Sara Tomechko, Janna Kiselar, Wuxian Shi, Galahad Deperalta, Aaron T Wecksler, Giridharan Gokulrangan, Victor Ling & Mark R Chance. (2014) Characterizing monoclonal antibody structure by carbodiimide/GEE footprinting. mAbs 6:6, pages 1486-1499.
Read now
Antonio da Silva, Ulrich Kronthaler, Vera Koppenburg, Martin Fink, Ines Meyer, Anastassia Papandrikopoulou, Matthias Hofmann, Thomas Stangler & Jan Visser. (2014) Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013. Leukemia & Lymphoma 55:7, pages 1609-1617.
Read now
Zayrho Desanvicente-Celis, Julian Caro-Moreno, Mateo Enciso-Zuluaga & Juan-Manuel Anaya. (2013) Similar biotherapeutic products in Latin America. Regulation and opportunities for patients with autoimmune diseases. Biosimilars 3, pages 1-17.
Read now
Alain Beck & Janice M. Reichert. (2013) Approval of the first biosimilar antibodies in Europe. mAbs 5:5, pages 621-623.
Read now
Daniel Ayoub, Wolfgang Jabs, Anja Resemann, Waltraud Evers, Catherine Evans, Laura Main, Carsten Baessmann, Elsa Wagner-Rousset, Detlev Suckau & Alain Beck. (2013) Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques. mAbs 5:5, pages 699-710.
Read now
Rabah Gahoual, Alicia Burr, Jean-Marc Busnel, Lauriane Kuhn, Phillipe Hammann, Alain Beck, Yannis-Nicolas François & Emmanuelle Leize-Wagner. (2013) Rapid and multi-level characterization of trastuzumab using sheathless capillary electrophoresis-tandem mass spectrometry. mAbs 5:3, pages 479-490.
Read now
Paul J Declerck & Steven Simoens. (2012) A European perspective on the market accessibility of biosimilars. Biosimilars 2, pages 33-40.
Read now
Alexey A. Lugovskoy, Janice M. Reichert & Alain Beck. (2012) 7th Annual European Antibody Congress 2011. mAbs 4:2, pages 134-152.
Read now

Articles from other publishers (126)

Greg Cantin, Qian Liu, Bhavana Shah, Scott Kuhns, Mats Wikström, Shawn Cao & Jennifer Liu. (2023) Analytical and Functional Similarity of the Biosimilar Candidate ABP 654 to Ustekinumab Reference Product. Drugs in R&D 23:4, pages 421-438.
Crossref
Atilio Tomazini & Julia M. Shifman. (2023) Targeting Ras with protein engineering. Oncotarget 14:1, pages 672-687.
Crossref
Austin Kulasekararaj, Robert Brodsky, Alexander Kulagin & Jun Ho Jang. (2022) Biosimilars in rare diseases: a focus on paroxysmal nocturnal hemoglobinuria. Haematologica 108:5, pages 1232-1243.
Crossref
Reza Safaei Nodehi, Behjat Kalantari, Jahangir Raafat, Nafiseh Ansarinejad, Vahid Moazed, Seyed Mohammad Reza Mortazavizadeh, Mehran Hosseinzadeh, Bayazid Ghaderi, Arash Jenabian, Mojtaba Qadyani, Shirin Haghighat, Abolghasem Allahyari, Mehrzad Mirzania, Mohammad Seghatoleslami, Mehrdad Payandeh, Afsaneh Alikhasi, Hamidreza Kafi & Farhad Shahi. (2022) A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients. BMC Pharmacology and Toxicology 23:1.
Crossref
Yanchao Wang, Chen Zheng, Chao Zhuang, Qiang Fu, Baohong Zhang, Yanling Bian, Nianmin Qi & Jianwei Zhu. (2022) Characterization and pre-clinical assessment of a proposed biosimilar to its originator Omalizumab. European Journal of Pharmaceutical Sciences 178, pages 106292.
Crossref
Albert J. Czaja. (2022) Advancing Biologic Therapy for Refractory Autoimmune Hepatitis. Digestive Diseases and Sciences 67:11, pages 4979-5005.
Crossref
Soojin Hwang, Beom Hee Lee, Woo-Shik Kim, Dae-Seong Kim, Chong Kun Cheon, Chang Hwa Lee, Yunha Choi, Jin-Ho Choi, Ja Hye Kim & Han-Wook Yoo. (2022) A phase II, multicenter, open-label trial to evaluate the safety and efficacy of ISU303 (Agalsidase beta) in patients with Fabry disease. Medicine 101:37, pages e30345.
Crossref
Busra Gurel, Melike Berksoz, Eda Capkin, Ayhan Parlar, Meltem Corbacioglu Pala, Aylin Ozkan, Yılmaz Capan, Duygu Emine Daglikoca & Meral Yuce. (2022) Structural and Functional Analysis of CEX Fractions Collected from a Novel Avastin® Biosimilar Candidate and Its Innovator: A Comparative Study. Pharmaceutics 14:8, pages 1571.
Crossref
May Meltzer, Noam Eliash, Ziv Azoulay, Uzi Hadad & Niv Papo. (2022) In vitro inhibition of cancer angiogenesis and migration by a nanobody that targets the orphan receptor Tie1. Cellular and Molecular Life Sciences 79:6.
Crossref
Hezi Hayun, Valeria Arkadash, Amiram Sananes, Eyal Arbely, David Stepensky & Niv Papo. (2022) Bioorthogonal PEGylation Prolongs the Elimination Half-Life of N-TIMP2 While Retaining MMP Inhibition. Bioconjugate Chemistry 33:5, pages 795-806.
Crossref
Hope S. Rugo, Eduardo J. Pennella, Unmesh Gopalakrishnan, Miguel Hernandez-Bronchud, Jay Herson, Hans Friedrich Koch, Subramanian Loganathan, Sarika Deodhar, Ashwani Marwah, Alexey Manikhas, Igor Bondarenko, Joseph D. Parra, Maria Luisa T. Abesamis-Tiambeng, Charuwan Akewanlop, Ihor Vynnychenko, Virote Sriuranpong, Sirshendu Roy, Eduardo Patricio Yanez Ruiz, Abhijit Barve & Cornelius F. Waller. (2021) Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial. The Breast 58, pages 18-26.
Crossref
Hasumati Rahalkar, Alan Sheppard, Carlos Augusto Lopez-Morales, Luciano Lobo & Sam Salek. (2021) Challenges Faced by the Biopharmaceutical Industry in the Development and Marketing Authorization of Biosimilar Medicines in BRICS-TM Countries: An Exploratory Study. Pharmaceutical Medicine 35:4, pages 235-251.
Crossref
Hope S. Rugo, Eduardo J. Pennella, Unmesh Gopalakrishnan, Miguel Hernandez-Bronchud, Jay Herson, Hans Friedrich Koch, Subramanian Loganathan, Sarika Deodhar, Ashwani Marwah, Alexey Manikhas, Igor Bondarenko, Guzel Mukhametshina, Gia Nemsadze, Joseph D. Parra, Maria Luisa T. Abesamis-Tiambeng, Kakhaber Baramidze, Charuwan Akewanlop, Ihor Vynnychenko, Virote Sriuranpong, Gopichand Mamillapalli, Sirshendu Roy, Eduardo Patricio Yanez Ruiz, Abhijit Barve, Adolfo Fuentes-Alburo & Cornelius F. Waller. (2021) Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment 188:2, pages 369-377.
Crossref
Anita Afzali, Daniel Furtner, Richard Melsheimer & Philip J. Molloy. (2021) The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable. Advances in Therapy 38:5, pages 2077-2093.
Crossref
Krzysztof Bonek, Leszek Roszkowski, Magdalena Massalska, Wlodzimierz Maslinski & Marzena Ciechomska. (2021) Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment. Cells 10:2, pages 323.
Crossref
Yossra A. Trabik, Eman M. Moenes, Medhat A. Al-Ghobashy, Marianne Nebsen & Miriam F. Ayad. (2020) Analytical comparability study of anti-CD20 monoclonal antibodies rituximab and obinutuzumab using a stability-indicating orthogonal testing protocol: Effect of structural optimization and glycoengineering. Journal of Chromatography B 1159, pages 122359.
Crossref
Natália Sousa Freitas QUEIROZ, Rogerio SAAD-HOSSNE, Renata de Sá Brito FRÓES, Francisco Guilherme Cancela e PENNA, Stefania Burjack GABRIEL, Adalberta Lima MARTINS & Fabio Vieira TEIXEIRA. (2020) DISCONTINUATION RATES FOLLOWING A SWITCH FROM A REFERENCE TO A BIOSIMILAR BIOLOGIC IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS. Arquivos de Gastroenterologia 57:3, pages 232-243.
Crossref
Gareth P. Gregory, Christine Carrington, Chan Y. Cheah, Eliza A. Hawkes, Ian M. Irving, Jim Siderov & Stephen Opat. (2020) A consensus statement on the use of biosimilar medicines in hematology in Australia. Asia-Pacific Journal of Clinical Oncology 16:4, pages 211-221.
Crossref
Anne Bellon, Jessie Wang, Andrej Skerjanec, Maria Velinova, Daniel Dickerson, Ahad Sabet, Ly Ngo, Terry O'Reilly, Charles Tomek, Steven Schussler, Stefanie Schier‐Mumzhiu, Sreekanth Gattu, Sven D. Koch, Celine Schelcher, Miryana Dobreva, Anca Boldea, Roumen Nakov & Gordon P. Otto. (2020) A large multicentre, randomized, double‐blind, cross‐over study in healthy volunteers to compare pharmacokinetics, pharmacodynamics and safety of a pegfilgrastim biosimilar with its US‐ and EU‐reference biologics. British Journal of Clinical Pharmacology 86:6, pages 1139-1149.
Crossref
Michael Bernardes Ramos, Anna Erika Vieira de Araújo, Cristiane Pinheiro Pestana, Ana Paula Dinis Ano Bom, Renata Chagas Bastos, Aline de Almeida Oliveira, Patrícia Cristina da Costa Neves & Haroldo Cid da Silva Junior. (2020) Initial development of biosimilar immune checkpoint blockers using HEK293 cells. Protein Expression and Purification 170, pages 105596.
Crossref
Burkhard Otremba, Jens Borchardt, Andra Kuske, Maike Hollnagel-Schmitz & Florian O Losch. (2020) Real-world use and acceptance of rituximab biosimilars in non-Hodgkin lymphoma in an oncologist network in Germany. Future Oncology 16:15, pages 1001-1012.
Crossref
Kati Sarnola, Merja Merikoski, Johanna Jyrkkä & Katri Hämeen-Anttila. (2020) Physicians’ perceptions of the uptake of biosimilars: a systematic review. BMJ Open 10:5, pages e034183.
Crossref
Thomas C. Blevins, Abhijit Barve, Yaron Raiter, Patrick Aubonnet, Sandeep Athalye, Bin Sun & Rafael Muniz. (2019) Efficacy and safety of MYL‐1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch study. Diabetes, Obesity and Metabolism 22:3, pages 365-372.
Crossref
Mansoor A. Khan, Mohammed A. Aseeri, Majed A. Alshamrani, Abdelmajid H. Alnatsheh & Hani S. Alhamdan. (2020) Emerging Role of Biosimilars in Oncology-Hematology in Saudi Arabia: A Practical Perspective. Global Journal on Quality and Safety in Healthcare 3:1, pages 22-29.
Crossref
Hussain Dahodwala & Kelvin H Lee. (2019) The fickle CHO: a review of the causes, implications, and potential alleviation of the CHO cell line instability problem. Current Opinion in Biotechnology 60, pages 128-137.
Crossref
Frank K Agbogbo, Dawn M Ecker, Allison Farrand, Kevin Han, Antoine Khoury, Aaron Martin, Jesse McCool, Ulrike Rasche, Tiffany D Rau, David Schmidt, Ma Sha & Nicholas Treuheit. (2019) Current perspectives on biosimilars. Journal of Industrial Microbiology and Biotechnology 46:9-10, pages 1297-1311.
Crossref
Ben Caldwell. (2019) Variability of Biologics and its Impact on Biosimilar Development. European Medical Journal, pages 22-30.
Crossref
Ouafa Mkinsi, Salima Lefkir-Tafiani, Héla S, Srairi, Samir Kochbati, Yasser M. El Dershaby, Mohamed M. El Azhari, Sabrina A-I. Midjek & Aicha Ladjouze-Rezig. (2019) Regulatory Perspectives on Biopharmaceuticals for Chronic Inflammatory Diseases in North Africa: A Narrative Review. The Open Rheumatology Journal 13:1, pages 72-84.
Crossref
Chien-Lung Tu, Yi-Lin Wang, Teh-Min Hu & Li-Feng Hsu. (2019) Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU- Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?. BioDrugs 33:4, pages 437-446.
Crossref
Kerene A. Brown, Shanthi Rajendran, Jason Dowd & Derek J. Wilson. (2019) Rapid characterization of structural and functional similarity for a candidate bevacizumab (Avastin) biosimilar using a multipronged mass‐spectrometry‐based approach. Drug Testing and Analysis 11:8, pages 1207-1217.
Crossref
Liese Barbier, Paul Declerck, Steven Simoens, Patrick Neven, Arnold G. Vulto & Isabelle Huys. (2019) The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars. British Journal of Cancer 121:3, pages 199-210.
Crossref
Josef S Smolen, Joao Goncalves, Mark Quinn, Fabrizio Benedetti & Jake Yongkwon Lee. (2019) Era of biosimilars in rheumatology: reshaping the healthcare environment. RMD Open 5:1, pages e000900.
Crossref
R. Neethu & Timo Minssen. (2019) What lurks in the shadows of the openness hyperbole for biopharmaceuticals?. Drug Development Research 80:3, pages 282-284.
Crossref
JongAh Joanne Lee, Junmo Yang, Changsoo Lee, Youngjin Moon, Sehee Ahn & Jiyoon Yang. (2019) Demonstration of functional similarity of a biosimilar adalimumab SB5 to Humira®. Biologicals 58, pages 7-15.
Crossref
Sujoy Ghosh, Saptarshi Bose, Sandeep Gowda & Pradip Mukhopadhyay. (2019) Biosimilar insulins – What a clinician needs to know?. Indian Journal of Endocrinology and Metabolism 23:4, pages 400.
Crossref
Thomas C. Blevins, Abhijit Barve, Bin Sun, Yaron Raiter, Patrick Aubonnet, Rafael Muniz, Sandeep Athalye & Michael Ankersen. (2019) Efficacy and safety of MYL-1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study. Diabetes, Obesity and Metabolism 21:1, pages 129-135.
Crossref
Brian G. Feagan, Gordon Lam, Christopher Ma & Gary R. Lichtenstein. (2018) Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. Alimentary Pharmacology & Therapeutics 49:1, pages 31-40.
Crossref
J. O’Callaghan, S. P. Barry, M. Bermingham, J. M. Morris & B. T. Griffin. (2018) Regulation of biosimilar medicines and current perspectives on interchangeability and policy. European Journal of Clinical Pharmacology 75:1, pages 1-11.
Crossref
Jenna E. Gallegos, Christopher Boyer, Eleanore Pauwels, Warren A. Kaplan & Jean Peccoud. (2018) The Open Insulin Project: A Case Study for ‘Biohacked’ Medicines. Trends in Biotechnology 36:12, pages 1211-1218.
Crossref
Eduardo Cazap, Ira Jacobs, Ali McBride, Robert Popovian & Karol Sikora. (2018) Global Acceptance of Biosimilars: Importance of Regulatory Consistency, Education, and Trust. The Oncologist 23:10, pages 1188-1198.
Crossref
Po-Chih Wu, Yi-Chen Yang, Der-Yuan Wang & Hwei-Fang Cheng. 2018. Biopharmaceuticals. Biopharmaceuticals.
Thomas C. Blevins, Abhijit Barve, Bin Sun & Michael Ankersen. (2018) Efficacy and safety of MYL-1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III study. Diabetes, Obesity and Metabolism 20:8, pages 1944-1950.
Crossref
Stefan Mühlebach. (2018) Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach?. Advanced Drug Delivery Reviews 131, pages 122-131.
Crossref
Sumit Bhatnagar, Kirti Dhingra Verma, Yongjun Hu, Eshita Khera, Aaron Priluck, David E. Smith & Greg M. Thurber. (2018) Oral Administration and Detection of a Near-Infrared Molecular Imaging Agent in an Orthotopic Mouse Model for Breast Cancer Screening. Molecular Pharmaceutics 15:5, pages 1746-1754.
Crossref
Steven R. Feldman, Jerry Bagel & Shahla Namak. (2018) Biosimilars for Immune-Mediated Chronic Diseases in Primary Care: What a Practicing Physician Needs to Know. The American Journal of the Medical Sciences 355:5, pages 411-417.
Crossref
Abigail Turner & John E. Schiel. (2018) Qualification of NISTmAb charge heterogeneity control assays. Analytical and Bioanalytical Chemistry 410:8, pages 2079-2093.
Crossref
Paul Cornes & Matti Aapro. (2018) The Impact of Biosimilars in Supportive Care in Cancer. European Oncology & Haematology 14:1, pages 20.
Crossref
Dzintars Gotham. (2018) Cell line access to revolutionize the biosimilars market. F1000Research 7, pages 537.
Crossref
Mary Ellen Cosenza. 2018. An Overview of FDA Regulated Products. An Overview of FDA Regulated Products 85 104 .
Christian Noe & Volker Baumann. 2017. Drug Selectivity. Drug Selectivity 101 133 .
Cristiane Barata-Silva, Rachel Ann Hauser-Davis, André Luiz Oliveira da Silva & Josino Costa Moreira. (2017) Desafios ao controle da qualidade de medicamentos no Brasil. Cadernos Saúde Coletiva 25:3, pages 362-370.
Crossref
Arnold G. Vulto & Orlando A. Jaquez. (2017) The process defines the product: what really matters in biosimilar design and production?. Rheumatology 56:suppl_4, pages iv14-iv29.
Crossref
Wojciech Jurczak, Ilídia Moreira, Govind Babu Kanakasetty, Eduardo Munhoz, Maria Asunción Echeveste, Pratyush Giri, Nelson Castro, Juliana Pereira, Luiza Akria, Sergey Alexeev, Eugeniy Osmanov, Peijuan Zhu, Siyka Alexandrova, Angela Zubel, Olof Harlin & Jutta Amersdorffer. (2017) Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. The Lancet Haematology 4:8, pages e350-e361.
Crossref
Christopher J. Webster & Gillian R. Woollett. (2017) A ‘Global Reference’ Comparator for Biosimilar Development. BioDrugs 31:4, pages 279-286.
Crossref
Albert Licollari, Katherine Riddle, Simon R. Taylor, Nuris Ledon & Gordon T. Bolger. (2017) Safety and Biosimilarity of ior®LeukoCIM Compared to Neupogen® Based on Toxicity, Pharmacodynamic, and Pharmacokinetic Studies in the Sprague-Dawley Rat. Journal of Pharmaceutical Sciences 106:6, pages 1475-1481.
Crossref
Othman Montacir, Houda Montacir, Murat Eravci, Andreas Springer, Stephan Hinderlich, Amirhossein Saadati & Maria Kristina Parr. (2017) Comparability study of Rituximab originator and follow-on biopharmaceutical. Journal of Pharmaceutical and Biomedical Analysis 140, pages 239-251.
Crossref
MA. Velasco-Velázquez, N. Salinas-Jazmín, E. Hisaki-Itaya, L. Cobos-Puc, W. Xolalpa, G. González, A. Tenorio-Calvo, N. Piña-Lara, LC. Juárez-Bayardo, LF. Flores-Ortiz, E. Medina-Rivero, NO. Pérez & SM. Pérez-Tapia. (2017) Extensive preclinical evaluation of an infliximab biosimilar candidate. European Journal of Pharmaceutical Sciences 102, pages 35-45.
Crossref
Peter M. Sullivan & Lisa M. DiGrazia. (2012) Analytic characterization of biosimilars. American Journal of Health-System Pharmacy 74:8, pages 568-579.
Crossref
Steven A. Berkowitz. 2017. Biosimilar Drug Product Development. Biosimilar Drug Product Development 15 82 .
Valeria Arkadash, Gal Yosef, Jason Shirian, Itay Cohen, Yuval Horev, Moran Grossman, Irit Sagi, Evette S. Radisky, Julia M. Shifman & Niv Papo. (2017) Development of High Affinity and High Specificity Inhibitors of Matrix Metalloproteinase 14 through Computational Design and Directed Evolution. Journal of Biological Chemistry 292:8, pages 3481-3495.
Crossref
S K Zyryanov & E A Ushkalova. (2016) Enoxaparin is a low-molecular-weight heparin with a complex chemical structure and various non-anticoagulant properties. Terapevticheskii arkhiv 88:12, pages 109-115.
Crossref
Reena Nair. 2016. Biosimilars of Monoclonal Antibodies. Biosimilars of Monoclonal Antibodies 269 281 .
Valderilio Azevedo, Brian Hassett, João Eurico Fonseca, Tatsuya Atsumi, Javier Coindreau, Ira Jacobs, Ehab Mahgoub, Julie O’Brien, Ena Singh, Steven Vicik & Brian Fitzpatrick. (2016) Differentiating biosimilarity and comparability in biotherapeutics. Clinical Rheumatology 35:12, pages 2877-2886.
Crossref
Huub Schellekens, Josef S Smolen, Mario Dicato & Robert M Rifkin. (2016) Safety and efficacy of biosimilars in oncology. The Lancet Oncology 17:11, pages e502-e509.
Crossref
Da Woon Sim, Kyung Hee Park, Hye Jung Park, Young Woong Son, Sang Chul Lee, Jung-Won Park & Jae-Hyun Lee. (2016) Clinical characteristics of adverse events associated with therapeutic monoclonal antibodies in Korea. Pharmacoepidemiology and Drug Safety 25:11, pages 1279-1286.
Crossref
Joshua M. Thurman & Moglie Le Quintrec. (2016) Targeting the complement cascade: novel treatments coming down the pike. Kidney International 90:4, pages 746-752.
Crossref
Krisztina B. Gecse & Péter L. Lakatos. (2016) Biosimilar Monoclonal Antibodies for Inflammatory Bowel Disease: Current Comfort and Future Prospects. Drugs 76:15, pages 1413-1420.
Crossref
Yeon Sook Cho, Byung Soo Kim, Chan Kyu Sim, Inki Kim & Myeong Sup Lee. (2016) Establishment of IL-7 Expression Reporter Human Cell Lines, and Their Feasibility for High-Throughput Screening of IL-7-Upregulating Chemicals. PLOS ONE 11:9, pages e0161899.
Crossref
Caroline Charles. (2016) The Evolving Biosimilar Landscape: Approval of the First Etanercept Biosimilar in Europe, An Interview With Emilio Martín-Mola. European Medical Journal, pages 76-84.
Crossref
D?nes Zalai, Helga Hev?r, Krisztina Lov?sz, D?ra Moln?r, Patrick Wechselberger, Alexandra Hofer, L?szl? P?rta, ?kos Putics & Christoph Herwig. (2016) A control strategy to investigate the relationship between specific productivity and high-mannose glycoforms in CHO cells. Applied Microbiology and Biotechnology 100:16, pages 7011-7024.
Crossref
Blair Hesp. (2016) Biosimilars: Shaping the Future of Haematology. EMJ Hematology, pages 30-37.
Crossref
Anurag S. Rathore, Mili Pathak, Renu Jain & Gaurav Pratap Singh Jadaun. (2016) Monitoring Quality of Biotherapeutic Products Using Multivariate Data Analysis. The AAPS Journal 18:4, pages 793-800.
Crossref
Eduardo Mysler, Carlos Pineda, Takahiko Horiuchi, Ena Singh, Ehab Mahgoub, Javier Coindreau & Ira Jacobs. (2016) Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology. Rheumatology International 36:5, pages 613-625.
Crossref
M. Tichy, R. Kopova & J. Sternbersky. (2016) First experience with therapy of severe forms of psoriasis with biosimilar infliximab. Journal of the European Academy of Dermatology and Venereology 30:3, pages 491-493.
Crossref
Matteo Ferrando, Diego Bagnasco, Fulvio Braido, Gilda Varricchi & Giorgio W. Canonica. (2016) Biosimilars in allergic diseases. Current Opinion in Allergy & Clinical Immunology 16:1, pages 68-73.
Crossref
Robert Eisenberg & Edward M. Behrens. 2016. Pediatric Allergy: Principles and Practice. Pediatric Allergy: Principles and Practice 160 166.e4 .
Gautam N. Allahbadia & Akanksha Allahbadia. 2016. Ovarian Stimulation Protocols. Ovarian Stimulation Protocols 71 77 .
Antonio da Silva & Didier Renard. 2016. Pharmacokinetics in Drug Development. Pharmacokinetics in Drug Development 175 188 .
Brian A. BaldoBrian A. Baldo. 2016. Safety of Biologics Therapy. Safety of Biologics Therapy 587 596 .
Jason J. Z. Liao. 2016. Nonclinical Statistics for Pharmaceutical and Biotechnology Industries. Nonclinical Statistics for Pharmaceutical and Biotechnology Industries 675 694 .
Lucy Smithers. (2015) Will Biosimilars Change the Treatment Paradigm in Psoriasis?. EMJ Dermatology, pages 39-46.
Crossref
Steven Jarrett & Theodor Dingermann. (2015) Biosimilars Are Here: A Hospital Pharmacist's Guide to Educating Health Care Professionals on Biosimilars. Hospital Pharmacy 50:10, pages 884-893.
Crossref
Lilian Rumi Tsuruta, Mariana Lopes dos Santos & Ana Maria Moro. (2015) Biosimilars advancements: Moving on to the future. Biotechnology Progress 31:5, pages 1139-1149.
Crossref
G. Lie, S. Sciascia & M.J. Cuadrado. (2015) Biosimilar vs biological agents in rheumatology: When are biosimilar agents similar enough?. International Immunopharmacology 27:2, pages 220-223.
Crossref
Daan J.A. Crommelin, Vinod P. Shah, Imre Klebovich, Scott E. McNeil, Vera Weinstein, Beat Flühmann, Stefan Mühlebach & Jon S.B. de Vlieger. (2015) The similarity question for biologicals and non-biological complex drugs. European Journal of Pharmaceutical Sciences 76, pages 10-17.
Crossref
Canna Ghia, Disheet Shah, Gautam Rambhad, Asia Mubashir & Sundeep Upadhyaya. (2015) Biologics, biosimilars, intended copies and the era of competitive medicine. Apollo Medicine 12:2, pages 103-111.
Crossref
Carlos A. López-Morales, Mariana P. Miranda-Hernández, L. Carmina Juárez-Bayardo, Nancy D. Ramírez-Ibáñez, Alexis J. Romero-Díaz, Nelly Piña-Lara, Víctor R. Campos-García, Néstor O. Pérez, Luis F. Flores-Ortiz & Emilio Medina-Rivero. (2015) Physicochemical and Biological Characterization of a Biosimilar Trastuzumab. BioMed Research International 2015, pages 1-10.
Crossref
Masayuki Isa, Daisuke Asanuma, Shigeyuki Namiki, Kazuo Kumagai, Hirotatsu Kojima, Takayoshi Okabe, Tetsuo Nagano & Kenzo Hirose. (2014) High-Throughput Screening System To Identify Small Molecules That Induce Internalization and Degradation of HER2. ACS Chemical Biology 9:10, pages 2237-2241.
Crossref
Dina Iezzi. (2014) Contract Development and Manufacturing Organizations (CDMO): are they needed in Brazil. BMC Proceedings 8:S4.
Crossref
Susanne D. Pippig, Carsten Brockmeyer & Robert E. Zoubek. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies 681 704 .
Young Sik Kim, Byung Wook Choi, Sung Wook Yang, Seon Mi Shin, Sang Wook Nam, Yun Sook Roh, Jae Young Lee, Kyung Jin Lee, Yong Jick Kim, Jun-Young Kwon & Dong-Il Kim. (2014) Biosimilars: Challenges and path forward. Biotechnology and Bioprocess Engineering 19:5, pages 755-765.
Crossref
Andreas Anton. (2014) Biosimilars — Warum es so schwer ist, Proteintherapeutika nachzuahmen. BIOspektrum 20:3, pages 346-348.
Crossref
Robert Eisenberg. 2014. Stiehm's Immune Deficiencies. Stiehm's Immune Deficiencies 889 906 .
Umang S. Shah. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia 1 42 .
Heather H. Shih, Paula Miller & Douglas C. Harnish. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia 1 28 .
Steven D. Lucio, James G. Stevenson & James M. Hoffman. (2013) Biosimilars: Implications for health-system pharmacists. American Journal of Health-System Pharmacy 70:22, pages 2004-2017.
Crossref
J Christopher Love, Kerry Routenberg Love & Paul W Barone. (2013) Enabling global access to high-quality biopharmaceuticals. Current Opinion in Chemical Engineering 2:4, pages 383-390.
Crossref
Soo Min Noh, Madhavi Sathyamurthy & Gyun Min Lee. (2013) Development of recombinant Chinese hamster ovary cell lines for therapeutic protein production. Current Opinion in Chemical Engineering 2:4, pages 391-397.
Crossref
Silvio Danese & Fernando Gomollon. (2013) ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). Journal of Crohn's and Colitis 7:7, pages 586-589.
Crossref
Niels S. Vermeer, Sabine M. J. M. Straus, Aukje K. Mantel-Teeuwisse, Francois Domergue, Toine C. G. Egberts, Hubert G. M. Leufkens & Marie L. De Bruin. (2013) Traceability of Biopharmaceuticals in Spontaneous Reporting Systems: A Cross-Sectional Study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance Databases. Drug Safety 36:8, pages 617-625.
Crossref
Alain Beck, Hélène Diemer, Daniel Ayoub, François Debaene, Elsa Wagner-Rousset, Christine Carapito, Alain Van Dorsselaer & Sarah Sanglier-Cianférani. (2013) Analytical characterization of biosimilar antibodies and Fc-fusion proteins. TrAC Trends in Analytical Chemistry 48, pages 81-95.
Crossref
Sara Rosati, Natalie J. Thompson, Albert J.R. Heck, Sara Rosati, Natalie J. Thompson & Albert J.R. Heck. (2013) Tackling the increasing complexity of therapeutic monoclonal antibodies with mass spectrometry. TrAC Trends in Analytical Chemistry 48, pages 72-80.
Crossref
Marcia Federici, Anthony Lubiniecki, Prakash Manikwar & David B. Volkin. (2013) Analytical lessons learned from selected therapeutic protein drug comparability studies. Biologicals 41:3, pages 131-147.
Crossref
Alexander Berghout, Andreas Premstaller & Mark McCamish. 2013. Modern Biopharmaceuticals. Modern Biopharmaceuticals 401 428 .
M McCamish & G Woollett. (2013) The Continuum of Comparability Extends to Biosimilarity: How Much Is Enough and What Clinical Data Are Necessary?. Clinical Pharmacology & Therapeutics 93:4, pages 315-317.
Crossref
L. Puig. (2013) Biosimilars in Dermatology: Starting With Infliximab. Actas Dermo-Sifiliográficas (English Edition) 104:3, pages 175-180.
Crossref
L. Puig. (2013) Biosimilares en dermatología: infliximab para empezar. Actas Dermo-Sifiliográficas 104:3, pages 175-180.
Crossref
James M. Hoffman, Edward Li, Fred Doloresco, Linda Matusiak, Robert J. Hunkler, Nilay D. Shah, Lee C. Vermeulen & Glen T. Schumock. (2013) Projecting future drug expenditures in U.S. nonfederal hospitals and clinics—2013. American Journal of Health-System Pharmacy 70:6, pages 525-539.
Crossref
Rolando Espinosa Morales, Alejandro D?az Borj?n, Leonor Adriana Barile Fabris, Jorge Antonio Esquivel Valerio, Gabriel Medrano Ram?rez, C?sar Alejandro Arce Salinas, Eduardo Rub?n Barreira Mercado, Mario Humberto Cardiel R?os, Efra?n D?az Jouanen, Francisco Javier Flores Murrieta, Antonio Fraga Mouret, Mario Alberto Garza Elizondo, Miguel Luj?n Estrada, Francisco Jos? Mu?oz Barradas, Juan Osvaldo Talavera Pi?a & Olga Lidia Vera Lastra. (2013) Biosimilar Drugs in Mexico: Position of the Mexican College of Rheumatology, 2012. Reumatolog?a Cl?nica (English Edition) 9:2, pages 113-116.
Crossref
Rolando Espinosa Morales, Alejandro D?az Borj?n, Leonor Adriana Barile Fabris, Jorge Antonio Esquivel Valerio, Gabriel Medrano Ram?rez, C?sar Alejandro Arce Salinas, Eduardo Rub?n Barreira Mercado, Mario Humberto Cardiel R?os, Efra?n D?az Jouanen, Francisco Javier Flores Murrieta, Antonio Fraga Mouret, Mario Alberto Garza Elizondo, Miguel Luj?n Estrada, Francisco Jos? Mu?oz Barradas, Juan Osvaldo Talavera Pi?a & Olga Lidia Vera Lastra. (2013) Medicamentos biocomparables en M?xico: la postura del Colegio Mexicano de Reumatolog?a, 2012. Reumatolog?a Cl?nica 9:2, pages 113-116.
Crossref
Jason J.Z. LiaoPatrick F. Darken. (2013) Comparability of critical quality attributes for establishing biosimilarity. Statistics in Medicine 32:3, pages 462-469.
Crossref
Bruno Calo-Fernández & Juan Martínez-Hurtado. (2012) Biosimilars: Company Strategies to Capture Value from the Biologics Market. Pharmaceuticals 5:12, pages 1393-1408.
Crossref
Zayrho Desanvicente-Celis, Arley Gomez-Lopez & Juan-Manuel Anaya. (2012) Similar biotherapeutic products: overview and reflections. Immunotherapy 4:12, pages 1841-1857.
Crossref
Abdol Majid Cheraghali. (2012) Biosimilars; a unique opportunity for Iran national health sector and national pharmaceutical industry. DARU Journal of Pharmaceutical Sciences 20:1.
Crossref
Zsuzsanna Kálmán-Szekeres, Marcell Olajos & Katalin Ganzler. (2012) Analytical aspects of biosimilarity issues of protein drugs. Journal of Pharmaceutical and Biomedical Analysis 69, pages 185-195.
Crossref
Morton A. Scheinberg & Jonathan Kay. (2012) The advent of biosimilar therapies in rheumatology—“O Brave New World”. Nature Reviews Rheumatology 8:7, pages 430-436.
Crossref
Steven A. Berkowitz, John R. Engen, Jeffrey R. Mazzeo & Graham B. Jones. (2012) Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nature Reviews Drug Discovery 11:7, pages 527-540.
Crossref
Alain Beck, Sarah Sanglier-Cianférani & Alain Van Dorsselaer. (2012) Biosimilar, Biobetter, and Next Generation Antibody Characterization by Mass Spectrometry. Analytical Chemistry 84:11, pages 4637-4646.
Crossref
Guillermina Forno & Eduardo Orti. (2017) Biosimilars: Current situation and future expectations. European Journal of Risk Regulation 3:2, pages 213-218.
Crossref
Jun Wang & Shein-Chung Chow. (2012) On the Regulatory Approval Pathway of Biosimilar Products. Pharmaceuticals 5:4, pages 353-368.
Crossref
Patricia Gravel, Aarti Naik & Jean-Yves Le Cotonnec. (2012) Biosimilar rhG-CSFs: how similar are they?. Targeted Oncology 7:S1, pages 3-16.
Crossref
Islah Ahmed, Ben Kaspar & Uma Sharma. (2012) Biosimilars: Impact of Biologic Product Life Cycle and European Experience on the Regulatory Trajectory in the United States. Clinical Therapeutics 34:2, pages 400-419.
Crossref
Paul Saenger. (2011) Biosimilar Growth Hormone. The Indian Journal of Pediatrics 79:1, pages 92-98.
Crossref
Paula C. Miller & Peiling Xu. 2012. Development of Antibody-Based Therapeutics. Development of Antibody-Based Therapeutics 355 373 .
George Dranitsaris, Eitan Amir & Kristine Dorward. (2011) Biosimilars of Biological Drug Therapies. Drugs 71:12, pages 1527-1536.
Crossref
Jorge Mestre-Ferrandiz & Adrian Towse. (2014) What is the Role of HTA for Biosimilars?. SSRN Electronic Journal.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.